Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed ...

Related Keywords

Japan ,Cambridge ,Cambridgeshire ,United Kingdom ,United States ,Canada ,America ,American ,Daiichi Sankyo Enhertu ,Daiichi Sankyo ,Daiichi Sankyo Company ,American Society Of Clinical Oncology ,Arch Pathol Lab ,European Commission ,Nasdaq ,Merck Co Inc ,Company On Twitter Astrazeneca ,Astrazeneca ,Committee For Medicinal Products Human ,Investor Relations Team ,European Union ,International Agency Of Cancer Research ,American Cancer Society ,Medicinal Products ,Human Use ,American Society ,Clinical Oncology ,New England Journal ,Sankyo Company ,Rare Diseases ,Cancer Statistics ,Mortality Worldwide ,Accessed January ,Epidermal Growth Factor Receptor ,Mol Biol ,Lancet Oncol ,Breast Cancer Hormone Receptor ,